Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 12:12 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1969–1992 of 4,023 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 3 Clear all

Conditions: Systemic Lupus Erythematosus, Quality of Life, Behavior, Health
Interventions: Peer Mentoring, Social Support Group; Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older · Female only
Enrollment: 314 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Post-Essential Thrombocythemia MF (Post-ET-MF)
Interventions: KRT-232, Best Available Therapy (BAT); Drug
Lead sponsor: Kartos Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 385 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 19
States / cities: Birmingham, Alabama • Los Angeles, California • Stanford, California + 14 more

Conditions: Systemic Sclerosis (SSc)
Interventions: Diet 1: Restriction of fermentable carbohydrates, Diet 2: Elimination of foods harmful to gut barrier and microbiome, Diet 3: Regular meal patterns, soluble fiber, and portion control; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Thyroid Eye Disease (TED)
Interventions: VV-14305, Sham (No Treatment); Genetic · Other
Lead sponsor: Kriya Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 3
States / cities: Livonia, Michigan • Las Vegas, Nevada • Erie, Pennsylvania

Conditions: Advanced Non-Central Nervous System (CNS) Malignancies
Interventions: Oprozomib, Midazolam; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 7
States / cities: Aurora, Colorado • Atlanta, Georgia • Detroit, Michigan + 4 more

Conditions: Breast Cancer
Interventions: Abemaciclib, Letrozole; Drug
Lead sponsor: Mridula George, MD; Other
Eligibility: 60 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 4
States / cities: Belleville, New Jersey • Livingston, New Jersey • New Brunswick, New Jersey + 1 more

Conditions: Fruit and Vegetable Consumption
Interventions: Mobile Market program implementation; Other
Lead sponsor: University at Buffalo; Other
Eligibility: 18 Years and older
Enrollment: 759 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Non-small Cell Lung Cancer
Interventions: ISIS EIF4E Rx, Paclitaxel, Carboplatin; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 10
States / cities: Birmingham, Alabama • Fayetteville, Arkansas • Hot Springs, Arkansas + 6 more

Conditions: Healthy, Obese
Interventions: LY3502970; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 3
States / cities: Daytona Beach, Florida • Dallas, Texas • Madison, Wisconsin

Conditions: Tobacco Use Disorder
Interventions: Camel Snus, Marlboro Snus, Stonewall, Ariva, General Snus; Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 70 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Eugene, Oregon

Conditions: Asthma
Interventions: I Can Cope Intervention, Standard Education Intervention; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 8 Years to 14 Years
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Follicular Lymphoma (FL)
Interventions: Odronextamab, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone/prednisolone, Bendamustine; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 822 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 20
States / cities: Tucson, Arizona • Los Angeles, California • Orange, California + 17 more

Conditions: Healthy Volunteers
Interventions: BMS-986460; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Cutaneous T-cell Lymphoma, T-Prolymphocytic Leukemia, T-Large Granulocytic Leukemia, T-Lymphoblastic Leukemia/Lymphoma, Peripheral T-Cell Lymphoma
Interventions: Romidepsin, Busulfan, Fludarabine, Stem Cell Transplant, Thymoglobulin; Drug · Procedure
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Adolescent - Emotional Problem, Suicide and Self-harm, Parenting
Interventions: DBT-Based Parenting Intervention, Treatment as Usual; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 13 Years to 18 Years
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Bone Metastases, Castration-Resistant Prostate Cancer
Interventions: Radium-223 dichloride (Xofigo, BAY88-8223), Docetaxel; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 6
States / cities: San Francisco, California • Evanston, Illinois • Baltimore, Maryland + 3 more

Conditions: Hiv
Interventions: NP-PC PrEP, OBGYN-PrEP; Other
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: For New York State Registered Family Practitioners and Internal Medicine Physicians
Interventions: in-depth, semi-structured interviews; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Advanced Melanoma, Metastatic Melanoma
Interventions: Nivolumab, Ipilimumab; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 12
States / cities: Los Angeles, California • Chicago, Illinois • Lutherville, Maryland + 7 more

Conditions: Psychosis
Interventions: PsyGist and Clinician Manual; Behavioral
Lead sponsor: New York University; Other
Eligibility: 16 Years to 30 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Deep Vein Thrombosis
Interventions: Whole-leg compression ultrasound; Other
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 18 Years and older · Female only
Enrollment: 268 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 1
States / cities: Murray, Utah

Conditions: Exocrine Pancreatic Insufficiency, Cystic Fibrosis
Interventions: Liprotamase Powder for Oral Solution; Drug
Lead sponsor: Anthera Pharmaceuticals; Industry
Eligibility: 28 Days and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 21
States / cities: Little Rock, Arkansas • Orange, California • Aurora, Colorado + 17 more

Conditions: Sarcoma
Interventions: Ra-223 Dichloride; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 15 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Anaemia
Interventions: GSK1278863 75 mg, GSK1278863 500 mg, Moxifloxacin 400 mg, Placebo matching GSK1278863, Placebo matching Moxifloxacin; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Overland Park, Kansas

Search by objective public record fields.

Peer Approaches to Lupus Self-management

KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment

Systemic Sclerosis DIet for GastrointESTinal Symptoms

A Study of VV-14305 for the Treatment of Thyroid Eye Disease

A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction With Midazolam, and Safety and Tolerability in Patients With Advanced Malignancies

RADIANT: Pre-op Radiation With Abemaciclib and Letrozole

Effectiveness and Implementation of a Research Tested Mobile Produce Market

Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin and Paclitaxel

A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants

Evaluation of Oral Tobacco as a Harm Reduction Method for Smokers

A Pilot Stress Management Intervention Study for High Risk Children With Asthma

A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

A Single-dose Study to Evaluate the Safety, Tolerability, Drug Levels, and Relative Biological Availability of Alternate Formulations of BMS-986460 in Healthy Adult Male Participants

Romidepsin Maintenance After Allogeneic Stem Cell Transplantation

DBT-Based Parenting Intervention for Parents of Youth at Risk for Suicide

A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)

Testing Two Models of PrEP Delivery in OBGYN Clinics

Community Primary Care Providers to Implement and Disseminate Cancer Prevention Interventions for Latino Populations

PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma

Developing Clinical Tools to Communicate Genetic Risk for Individuals Who Are Clinical High Risk for Psychosis

Whole-leg Ultrasound in Pregnant Patients

SIMPLICITY: Studying Impacts on Malabsorption With Liprotamase in Cystic Fibrosis

Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma

Single Dose, Pharmacokinetic, Safety, Tolerability and QTc Study of GSK1278863 in Healthy Volunteers